JPMorgan analyst Anupam Rama lowered the firm’s price target on Sarepta (SRPT) to $84 from $169 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect its lower net product guidance and lower peak sales or Elevidys.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Positive Outlook for Sarepta Therapeutics Amid Elevidys Expansion and Strategic Collaborations
- Sarepta reports positive ELEVIDYS protein expression data in young patients
- Sarepta presents EMBARK study data at ASGCT conference
- Sarepta Therapeutics: Hold Rating Amid Limited Financial Gains from ELEVIDYS Approval and Market Adoption Concerns
- Sarepta announces Japan approval for Elevidys
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue